REVIEW article
Front. Oncol.
Sec. Cancer Genetics
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1570030
This article is part of the Research TopicMolecular Pathways and Signaling Molecules in Cancer Therapy: Advances and InnovationsView all 11 articles
Research progress on sirtuin family genes in colorectal cancer
Provisionally accepted
- 1Zhongshan Hospital of Traditional Chinese Medicine Affiliated to Guangzhou University of Traditional Chinese Medicine, Zhongshan, China
- 2Hebei North University, Zhangjiakou, Hebei Province, China
- 3The Third Xiangya Hospital, Central South University, Changsha, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Sirtuins are a highly conserved family of NAD⁺-dependent deacetylases involved in regulating critical biological processes such as cell survival, antioxidation, gene transcription, proliferation, differentiation, DNA repair, and mitochondrial function.Recent studies have revealed that altered expression of sirtuin family genes in mammals is closely linked to the development of various diseases, including metabolic disorders, ageing, and cancer. In colorectal cancer (CRC), sirtuins play dual regulatory roles, modulating tumour cell proliferation, migration, invasion, and apoptosis while also activating pro-oncogenic signalling pathways or suppressing tumour progression, depending on context. This review systematically summarizes the research progress on sirtuin family genes in CRC, highlighting their dual roles (pro-tumorigenic and tumoursuppressive) and molecular mechanisms. These findings underscore the potential of sirtuins as therapeutic targets in CRC. The development of selective activators or inhibitors, combined with metabolic interventions or immunotherapy, may provide novel strategies for precision CRC treatment.
Keywords: Sirtuin family, colorectal cancer, metabolic reprogramming, Epigenetic regulation, targeted therapy
Received: 27 Feb 2025; Accepted: 08 Sep 2025.
Copyright: © 2025 Liu, Wu, Li, Luo and Minglin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Zhang Minglin, The Third Xiangya Hospital, Central South University, Changsha, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.